Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 8/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936572 | 1.00 | VCAM1 (0.56) | VCAM1KDM1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL28555521 | 0.87 | SMN1; SMN2 (0.59) | VCAM1KDM1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6349993 | 0.87 | TSHR (0.53) | VCAM1KDM1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13239653 | 0.85 | VCAM1 (0.50) | VCAM1SMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL27986576 | 0.84 | HTR1A (0.50) | SMN1; SMN2MEN1KMT2ALMNAMAPT | |
| SCHEMBL8901138 | 0.82 | VCAM1 (0.46) | VCAM1KDM1ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9524443 | 0.80 | VCAM1 (0.48) | VCAM1KDM1ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL628111 | 0.80 | ALDH1A1 (0.45) | VCAM1KDM1ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL1601110 | 0.80 | IDH1 (0.58) | SMN1; SMN2MEN1KMT2ALMNAMAPT | |
| SCHEMBL10652958 | 0.80 | CES2 (0.53) | SMN1; SMN2MEN1KMT2ALMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2023-07-20 | — | — | US | disclosed |
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2023-07-20 | — | — | US | disclosed |
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2023-07-20 | — | — | US | disclosed |
| WO-2021099803-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2021-05-27 | — | — | WO | disclosed |
| EP-0268849-B1 | Poly(aminoaromatic) compounds | DOW CHEMICAL CO (US) | 1993-10-20 | — | — | EP | disclosed |
| US-5079275-A | Polyamino compound is an amino endcapped polyether, polyester, polycarbonate, resole, hydroxybutadiene | THE DOW CHEMICAL COMPANY (US) | 1992-01-07 | — | — | US | disclosed |
| US-4847416-A | Capping of polyols with aromatic amines | THE DOW CHEMICAL COMPANY (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0268849-A2 | Poly(aminoaromatic) compounds | THE DOW CHEMICAL COMPANY (US) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | HMBS, POR, CYP2A13 | VCAM1 4637/4885KDM1A 2675/4885SMN1; SMN2 4655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.